Preventive Health for Men Over 50
The numbers worth tracking, which screenings have evidence behind them, and which expensive tests I decided to skip. Written by a patient who reads the guidelines, not a doctor who writes them.
By Gunnar · Patient experience, not medical advice · Updated August 2026

Where each of these numbers comes from
Unlike a single-trial chart, this one pulls from four different bodies, so each row names its own rather than pretending they are one set. All verified against the source documents in August 2026.
| Number | Source, and the exact wording |
|---|---|
| Blood pressure | 2025 AHA/ACC high blood pressure guideline. Normal is defined as under 120 and under 80, and that is the number this page tells you to aim for. The guideline’s formal treatment goal is the looser <130/80 mm Hg, with exceptions for people in institutional care, with limited life expectancy, or who are pregnant. So 130/80 is where the guideline says treatment has done its job, and 120/80 is the line it calls normal. Commentaries on the guideline describe it as encouraging people below 120/80 as well, but that is their characterisation and not wording I have been able to check in the guideline itself. Stage 1 hypertension is 130 to 139 or 80 to 89. |
| LDL cholesterol | 2026 ACC/AHA dyslipidemia guideline. Its goals come as pairs with non-HDL cholesterol: <100 (non-HDL <130) at borderline to intermediate risk, <70 (non-HDL <100) at high risk or with subclinical atherosclerosis, and <55 (non-HDL <85) for clinical ASCVD that is at very high risk. That last split is the one people get wrong: having heart disease does not automatically put you at 55. The guideline gives <70 to clinical ASCVD that is not very high risk, and defines very high risk as two or more major events, or one major event plus two or more high-risk features. |
| ApoB | 2026 ACC/AHA dyslipidemia guideline, which calls apoB measurement “reasonable” for adults already on lipid-lowering therapy, to guide further treatment once the LDL and non-HDL goals are met. It is a refinement test rather than a universal one, and the reason to bother is discordance: LDL can read at goal while apoB stays elevated. The two apoB goals stated in its recommendation text are <100 mg/dL alongside the LDL <100 goal, and <55 mg/dL at the severe and very-high-risk end once the LDL and non-HDL goals are met. |
| A1C | American Diabetes Association, Standards of Care in Diabetes—2026, section 2. Its table 2.2 defines prediabetes as A1C 5.7 to 6.4%, and table 2.1 diagnoses diabetes at A1C 6.5% or above on a lab test standardised to the reference assay. The ADA adds the part worth carrying: for all of these tests “risk is continuous, extending below the lower limit of the range”, so 5.6 is not a safe zone and these are the lines where a diagnosis starts, not treatment targets. Someone already diagnosed sets a different goal with their doctor. |
| Waist | NICE guideline NG246: keep your waist to less than half your height, a ratio under 0.5. It classifies 0.4 to 0.49 as healthy, 0.5 to 0.59 as increased and 0.6 or more as high central adiposity, for adults with a BMI under 35 of any sex or ethnicity, including people carrying a lot of muscle. |
What men over 50 should know
The measurable part of preventive health after 50 comes down to five numbers, and almost nobody hands you the list. I had to assemble mine from four different guidelines, which is a ridiculous amount of work for something this basic. The one that surprised me is blood pressure. Under 120 over 80 is what actually counts as normal, and it is what I aim for. The formal treatment goal in the 2025 guideline is the looser under 130 over 80. Two real numbers, constantly confused for each other, and the gap between them is where a lot of men sit and assume they are fine.
The boring numbers are the ones with the evidence, which is not how any of this gets sold. A blood pressure cuff costs almost nothing and it is the reason I take a pill every morning. A tape measure around your waist is simpler than BMI, and it tracks the fat that does the damage, and the rule is easy enough to remember: keep it under half your height. Meanwhile the things being advertised to men my age, the full-body MRI, the hundred-biomarker panel, the biological-age report, come with no target and no evidence that ordering them makes you healthier. I am not immune to wanting them. I have written about how fast that curiosity turns into shopping, and about the version that costs forty thousand dollars a year.
I am a patient here, not a clinician, and I track these because I got the bad version of the news first. My own cholesterol panel is the reason I care that apoB and LDL can disagree, and that the number your doctor quotes depends on a risk score rather than your birthday. The rest of this page is what I have read and checked: the screenings worth having, the ones that are genuinely your call, and the expensive tests I decided to skip. Where the evidence is thin I say so, because a test that finds something you would never have died from still gets you the biopsy, the scan, and the year of worrying.
Start here: the screening decisions
- The blood pressure guidelines changed a calculator, not the categories
What actually moved in 2025, and why most of the panic was aimed at the wrong thing. I take the pill, so I went and read it. - Colon screening added a blood test, and it is the one I would pick last
More options is not the same as equal options. Where the new blood draw actually sits against a colonoscopy. - I got Shingrix to avoid my wife’s misery
Then the dementia and cardiovascular data showed up. The clearest risk-benefit call I have made in years. - The lung-cancer blood test I am watching, not ordering
Fourteen proteins that show up years before a diagnosis, and the honest distance between that finding and a test you can use.
What you are being sold
- The $40,000 longevity membership, and the garage version
What the concierge tier actually buys you on top of the biology, which costs a few thousand a year. - The functional medicine empire
What it is, what it sells, and the specific points where it stops being your primary care doctor under a nicer brand. - At some point biohacking just becomes shopping
I feel the pull too. Where curiosity about your own body turns into a cart full of tests nobody has shown help. - NAD+: what the research actually says
One of the most heavily marketed supplements aimed at men our age, held against its own evidence.
Sleep, recovery and the daily inputs
- Sleep after 50: my data did not say what I thought it said
I pulled a year of my own numbers expecting a success story. Recomputing from the raw data took it away. - Cold plunges got the hype, saunas got the evidence
One of the two has long-term mortality data behind it, and it is not the one filling your feed. - Cycling and dementia risk: what the data actually says
A 22 percent headline, and the gap between what the study measured and what it was reported to mean. - The 2.5-hour morning routine, start to finish
The full blueprint version: a 5:45 wake-up, hydration, the weigh-in, and the training block.
Latest in Preventive Health
-

The First Big Lp(a) Drug Trial Missed Its Main Goal. It Put LDL Back at the Top of My List.
Pelacarsen missed its primary endpoint in the Lp(a)HORIZON trial. Here’s what’s actually known, what two doctors think happened, and why…
-

Retatrutide Cost: No Price Yet, and My Estimate Is $450 to $650 a Month
I paid Lilly’s self-pay price for Zepbound for months, and retatrutide has no announced price yet, so here is what…
-

Does CagriSema Have a Brand Name Yet?
CagriSema has no announced brand name as of September 4, 2026. Novo Nordisk owns eleven invented names it could use,…
-

Does Retatrutide Have a Brand Name Yet?
Retatrutide still has no brand name. But Lilly filed 20 new trademarks in a month and 19 are built on…
-

Retatrutide vs Zepbound: Is Lilly’s Next Weight-Loss Shot Worth Waiting For?
Retatrutide beat Zepbound’s numbers in its own trials, and it did not need its top dose to do it. I…
-

A Zero Calcium Score Isn’t the Whole Story. But the $2,000 Scan Isn’t Either.
My coronary calcium score is zero. What a zero doesn’t rule out, what a new NEJM study found about plaque…
-

Heart Attacks Were 43% Lower With a Statin in Adults Over 70. Cardiovascular Deaths Were Not.
I do not take a statin. I got my ApoB to 59 with about 170 pounds of weight loss and…
-

Moderna Nearly Tripled on a Cancer Vaccine Without Showing the Phase 3 Numbers
Melanoma flips male after 50 and keeps climbing. Merck and Moderna announced a Phase 3 win with no efficacy numbers…
